New drug combo targets tough breast cancer in 40-Patient trial
Disease control
Ongoing
This study tests a combination of two drugs, tucatinib and alpelisib, in 40 adults with a specific type of advanced HER2-positive breast cancer that has a PIK3CA gene mutation. The goal is to see if the combo is safe and can slow cancer growth. Participants must have cancer that …
Phase: PHASE1, PHASE2 • Sponsor: Criterium, Inc. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC